Shalby Ltd (SHALBY) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Shalby Ltd. reported consolidated revenue of Rs. 281 crores, a 27.4% increase year-over-year, driven by growth across hospital and implant segments.
- Standalone hospital revenue reached Rs. 227 crores, a 13.3% year-over-year increase.
- Shalby Sanar, while currently operating at a loss, is expected to achieve EBITDA positivity in the near future.
- The implant business demonstrated significant progress, with Shalby MedTech Limited achieving a 58% year-over-year revenue increase.
- Shalby continues to focus on clinical excellence, completing 26 transplants during the quarter and expanding its service offerings.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.